Biotek-snakken — December 2022
-
En lille forsinkelse på indsending af FDA ansøgning til 1 kv 23….vel ikke nogen katastrofe, men skal nok give lidt søgang og hysteri idag
XBRANE BIOPHARMA: ÅTERINLÄMNAD FDA-ANSÖKAN FÖRSENAS TILL 1 KV -
Godt nok en voldsom reaktion på 3 mndr forsinkelse, men sådan vurderer markedet åbenbart nyheden
-
XBrane fra Red Eye…. Our estimate changes slightly lower our base case to SEK180 (183) per share, suggesting a >100% upside from today’s levels levels of SEK81. Bull- and bear case amounts to SEK300 and SEK64. Accordingly, we consider today’s share price drop of ~10% as an overreaction and remain very optimistic about the investment case in Xbrane moving into 2023. https://www.redeye.se/research/868972/xbrane-biopharma-bla-re-submission-delayed-to-q1-2023?utm_source=note
-
Kort video: Anavex ' Genmab ' Bavarian Nordic ' Zealand Pharma ' Novo Nordisk
Helge Larsen gennemgår det sidste nye om selskaberne inden for pharma og biotek ud fra den kvalificerede debat og chat på Proinvestor.com https://www.proinvestor.com/boards/108744
-
Godmorgen .
-
Is Moderna Stock A Buy Following Skin Cancer Vaccine Progress?https://www.proinvestor.com/investornyt/916750/is-moderna-stock-a-buy-following-skin-cancer-vaccine-progress
-
Tyske Formycon (biosimilarer) i ATH…må vel også snart smitte af på XBrane…tyskerne tror ihvertfald på fremtiden
MarkedsoversigtFormycon AG
90,00 EUR
+7,10 (8,56 %)i dag -
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind